Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Sumitomo Dainippon Pharma Co ( (JP:4506) ) just unveiled an announcement.
Sumitomo Pharma Co., Ltd. announced its plan to transition to a company with an Audit and Supervisory Committee, pending approval at the upcoming Annual Shareholders’ Meeting. The Board of Directors has appointed candidates for executive and key personnel roles, with several directors and committee members being confirmed, subject to shareholder approval. This transition is expected to enhance the company’s governance structure, potentially impacting its operational oversight and strategic direction.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd., headquartered in Osaka, Japan, operates in the pharmaceutical industry, focusing on the development and commercialization of pharmaceutical products. The company is led by Representative Director, President and CEO, Toru Kimura.
Average Trading Volume: 5,624,664
Technical Sentiment Signal: Buy
Current Market Cap: Yen383B
Learn more about 4506 stock on TipRanks’ Stock Analysis page.